| NCT ID | NCT03216785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Critical Care |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2017-07-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2017-07-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective registry of patients admitted to the medical intensive care unit Patients discharged are followed up to 5 years after discharge
Eligibility Criteria
Inclusion Criteria: * Patients admitted to the medical intensive care unit Exclusion Criteria: * Patients admitted to the intensive care unit for simple procedures * Patients admitted for postoperative care observation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03216785 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Critical Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03216785 currently recruiting?
Yes, NCT03216785 is actively recruiting participants. Contact the research team at realrain7@gmail.com for enrollment information.
Where is the NCT03216785 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT03216785 clinical trial?
NCT03216785 is sponsored by Seoul National University Hospital. The trial plans to enroll 5,000 participants.